297 related articles for article (PubMed ID: 35261174)
1. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.
Varma M; Almarsdóttir AB; Druedahl LC
Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174
[TBL] [Abstract][Full Text] [Related]
2. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
[TBL] [Abstract][Full Text] [Related]
5. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
7. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
[TBL] [Abstract][Full Text] [Related]
10. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
11. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars for the treatment of psoriasis.
Puig L; López-Ferrer A
Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
[No Abstract] [Full Text] [Related]
13. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
15. A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology.
Gasteiger C; Scholz U; Petrie KJ; Dalbeth N
Rheumatol Int; 2022 Nov; 42(11):1993-2002. PubMed ID: 34705051
[TBL] [Abstract][Full Text] [Related]
16. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability.
Lasala R; Abrate P; Zovi A; Santoleri F
Ther Innov Regul Sci; 2023 Mar; 57(2):352-364. PubMed ID: 36322326
[TBL] [Abstract][Full Text] [Related]
18. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
[TBL] [Abstract][Full Text] [Related]
19. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
[TBL] [Abstract][Full Text] [Related]
20. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.
Armuzzi A; Avedano L; Greveson K; Kang T
J Crohns Colitis; 2019 Feb; 13(2):259-266. PubMed ID: 30285235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]